Physician profile
Brian Blair
NPI 1841587565
$861.40
in general payments reported to CMS, 2019-2025
13 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2023: $89.23 · 2024: $405 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.21 | 2019-2025 | |
| Conmed Corporation | $162.00 | 2024 | Conmed Biliary, Conmed Hemostasis |
| Janssen Biotech, INC. | $146.40 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.67 | 2024-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $46.71 | 2024 | |
| Steris Corporation | $44.31 | 2023 | |
| Lilly USA, LLC | $38.61 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $37.00 | 2025 | Rezdiffra |
| Celgene Corporation | $30.40 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $25.31 | 2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $20.65 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2025 | Entyvio |
| Celltrion USA INC. | $16.36 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.